I share the concerns of many of my colleagues who have heard from our constituents about a variety of problems that have...
Can we change that legislatively? Or is the clock going to run out as you come back to work?
Have you adapted that for Zoom? I mean, we are adapting everything for Zoom.
Well, you could, I think, help us if you could make a recommendation, again in the QFR window of this hearing.
I think these are good initiatives. They're really a top-down, not bottom-up approach.
I am supportive of doing something. I am actually not against this bill, but I think it's a piecemeal approach.
I think that regulatory reform and competition advocacy are very, very important.
I am also pleased to be in partnership with Representatives Johnson and Issa in a House companion to a bill.
Break them up. That is the remedy that I have advocated on some of the Big Tech companies.
We need to get that done immediately. That will add significant resources to the two agencies, plus the appropriations p...
It is outrageous that we still have this practice going on where pharmaceuticals are paying their competitors to keep th...
First, I would suggest negotiation of drug prices under Medicare, a bill that I lead with Representative Welch.
I want to thank Senators Grassley, Cornyn, and Klobuchar, and Blumenthal for their work on these important issues.
This legislation addresses product hopping, a particular abusive form of conduct used by drug manufacturers to extend th...
Today, pharmaceutical companies are confronting the American people with a terrible choice: Miss rent payments and skip ...
I look forward to joining Mr. Issa in reforming our Nation's patent laws.
to explicitly prohibit healthcare mergers that enable greater exploitation of existing market power and are likely to re...
You can't just do that and expect these healthcare pharma issues to be taken care of without funding those agencies.
